Who is sponsoring NCT02278315?

NCT02278315 is sponsored by Cellectar Biosciences, Inc..

What condition does NCT02278315 study?

NCT02278315 studies Multiple Myeloma.

What drugs are being tested in NCT02278315?

Interventions: I-131-CLR1404, dexamethasone, I-131-CLR1404.

What is the status of NCT02278315?

NCT02278315 is currently COMPLETED.

Last reviewed 2023-02-21 · How we verify

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

NCT02278315 Phase 1 COMPLETED

The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor.

Details

Lead sponsor	Cellectar Biosciences, Inc.
Phase	Phase 1
Status	COMPLETED
Enrolment	31
Start date	2015-02
Completion	2022-08-10

Conditions

Multiple Myeloma

Interventions

I-131-CLR1404
dexamethasone
I-131-CLR1404

Primary outcomes

Number of participants with dose limiting toxicities (DLT) — up to 85 days
DLT will be assessed by physical examination, vital signs, ECG, and laboratory values

Countries

United States